2023-07-12T15:22:25-07:00 2022-12-31 990 2022-01-01 824322538 AIM-HI ACCELERATOR FUND INC AIM- 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 Kwok Leung CFO 3019619115 2023-04-25 1 1 11 0 AAL2 2022 2023-04-26 12:10:37Z AIM HI TRANSLATIONAL RESEARCH INC SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 3905995 0 X WWW.AIM-HIACCELERATOR.ORG X 2019 MD The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients' lives. 7 7 0 10 0 0 3347719 3905995 0 0 4 0 0 0 3347723 3905995 0 35500 0 0 0 0 0 0 4676 6524 140185 6524 175685 3341199 3730310 9619722 13356814 630 7412 9619092 13349402 The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients' lives. 0 0 116181 35500 0 Leveraging immediately deployable venture philanthropy funding to provide seed funding and sustainable impact investment for oncology start-ups to bridge the "Valley of Death" funding gap and bring innovative new therapies, diagnostics and cancer prevention to patients. 0 0 0 116181 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 1 0 0 0 0 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X Kwok Leung 3019619115 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X CHARLIE WEATHERSPOON CHAIRMAN OF THE BOARD 2.50 X 0 0 0 MATT TREMBLAY VICE CHAIRMAN 1.50 X 0 0 0 FRANKLIN SALISBURY JR DIRECTOR 1.50 X 0 0 0 MARK BARAN DIRECTOR 1.50 X 0 0 0 YAJUN XU DIRECTOR 1.50 X 0 0 0 BRIAN LEYLAND-JONES DIRECTOR 1.50 X 0 0 0 ALFRED SLANETZ DIRECTOR 1.50 X 0 0 0 SUJUAN BA PRESIDENT/CEO 12 X 0 0 0 KWOK LEUNG TREASURER/SECRETARY 12 X 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3905995 1349999 3905995 0 0 0 0 0 0 0 3905995 0 0 0 35500 35500 11968 11968 0 1600 1600 86 86 45850 41174 4676 1538 1538 79143 79143 175685 116181 54828 4676 388825 670669 1005250 9230897 11680895 9619722 13356814 630 7412 630 7412 X 9619092 13349402 0 0 9619092 13349402 9619722 13356814 3730310 0 0 0 0 0 X 0 0 0 X 5812621 3345219 3905995 13063835 0 0 5812621 3345219 3905995 13063835 13063835 14109 4 14113 13077948 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED INTERLEUKIN COMBINATORIAL THERAPEUTICS INC 1748000 C INVAMET THERAPEUTICS INC 1267500 C ONCOHEROES BIOSCIENCES INC 500000 C RASIO THERAPEUTICS 1000000 C SCITECH DEVELOPMENT LLC 310332 C AKROTOME IMAGING INC 267566 C STROMATIS PHARMA 1037500 C PRIVO TECHNOLOGIES 300000 C WINDOW THERAPEUTICS 700000 C TVARDI THERAPEUTICS 500000 C TELLBIO INC 400000 C CATALIO GENESIS FUND 500000 C SPOROS BIOVENTURES LLC 999998 C YIVIVA INC 600000 C DOT-BIO PTE LTD 250000 C ARBELE INVESTMENT LIMITED 300000 C DRIVER BIO (CHIMERA) 999999 C 11680895 1 RIVERWALK THERAPEUTICS INC 8511 Mantano Ridge Helotes TX 78023 853970842 10000 CANCER RESEARCH BELIVER PHARMACEUTICALS INC 704 N King St Ste 500 Wilmington DE 19801 850881233 10000 CANCER RESEARCH 0 2 Schedule I, Part I, Line 2 Grant recipients are required to submit annual progress reports to our organization. X 1 499999 BOOK VALUE X 3 850000 BOOK VALUE 0 0 1 0 Form 990, Part VI, Section A, Line 2 BOARD DIRECTOR FRANKLIN SALISBURY, JR. AND CEO SUJUAN BA ARE HUSBAND AND WIFE. Form 990, Part VI, Section A, Line 7a AS THE INCORPORATOR AND THE INITIAL GRANTER TO THE ORGANIZATION, NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) HAS THE POWER TO APPOINT UP TO TWO (2) DIRECTORS TO THE GOVERNING BODY. THE APPOINTEES WILL NEVER CONSTITUTE MORE THAN FORTY (40) PERCENT OF ALL VOTING POWER. Form 990, Part VI, Section B, Line 11b REVIEW PROCESS OF FORM 990: (1) FORM 990 WILL BE PREPARED BY THE TREASURER AFTER THE ANNUAL FINANCIAL STATEMENTS ARE DONE; (2) THE FIRST DRAFT WILL BE REVIEWED BY THE CEO, (3) AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO THE BOARD OF DIRECTORS, PREFERABLY ELECTRONICALLY FOR THEIR RESPECTIVE REVIEW AND COMMENTS, (4) THE COMMENTS FROM BOARD OF DIRECTORS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN, (5) THE TAX RETURN (FORM 990 OR EQUIVALENT) WILL BE FILED WITH THE INTERNAL REVENUE SERVICE PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. (6) IN THE OCCASSION THAT THERE IS INSUFFICIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW BY THE BOARD PRIOR TO THE FILING DEADLINE, AN FILED COPY OF THE FORM WILL BE AVAILABLE FOR BOARD OF DIRECTORS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. Form 990, Part VI, Section B, Line 12c CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING THE POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT ANNUALLY IN WRITING TO THE BOARD OF DIRECTORS A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE ORGANIZATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST. Form 990, Part VI, Section B, Line 15 CURRENTLY ALL OFFICERS OF THE ORGANIZATION, INCLUDING CEO AND TREASURER, ARE PROVIDING PRO BONO SERVICE TO THE ORGANIZATION. IN THE FUTURE WHEN THE ORGANIZATION IS FINANCIALLY CAPABLE, THE BOARD OF DIRECTORS, ON AN ANNUAL BASIS, WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION FOR OFFICERS. THE PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS: (1) REVIEW AND APPROVAL BY THE BOARD OF DIRECTORS, BASED ON PERFORMANCE AND RESPONSIBILITIES, (2) REVIEW OF COMPENSATION DATA OF THE PEER ORGANIZATIONS OF THE ORGANIZATION, (3) DOCUMENTATION AND RECORDKEEPING COMPARABLE WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT, ARE KEPT BY THE SECRETARY OF THE ORGANIZATION. Form 990, Part VI, Section C, Line 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.